Aim: To determine the indicators of adherence to drug therapy in young patients with arterial hypertension (АН) and the correlation between the indicators and therapy management.Materials and methods: The study enrolled 514 patients aged 25 to 45 years diagnosed with essential hypertension. We studied the structure of antihypertensive pharmacotherapy and adherence to treatment using the Moriski−Green test and the original questionnaire. The patients were distributed depending on the degree of blood pressure increase, administered treatment, age, economic factor, and drug source.Results: The adherence level by Moriski−Green test was 36.8%; according to the original questionnaire: high adherence level was 38.3%, incomplete adherence ― 33.7%, and poor adherence ― 28.0%. The monotherapy with ACE inhibitors predominated in the majority of cases; the fixed combinations were more typical for the treatment of the stage II AH, drug combinations ― for stage III AH. The highest therapy adherence was registered in patients with stage III AH receiving treatment with combinations of drugs in a single dosage form. The life quality of respondents and the drug source did not influence the adherence significantly.Conclusion: In young patients with arterial hypertension, some features of treatment structure determine the therapy adherence.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.